Novo Nordisk A/S 🇩🇰
NVO • Energy • Denmark
💡 Institutional Quantitative Investment Thesis
High-quality compounder passing 8/9 fundamental checks. Strong balance sheet with Forward PER compression (1.7x vs 9.5x) and robust Free Cash Flow generation.
📊 Frequently Asked Questions & Related Moat Stocks
1. What is Novo Nordisk A/S (NVO)'s Economic Moat Score in 2026?
In 2026, Novo Nordisk A/S (NVO) holds a proprietary MoatPicks Economic Moat Score™ of 91.0/100 (Wide Economic Moat). This 12-point fundamental audit evaluates NVO's 82.0% gross margin, $37.7B free cash flow generation, +2.1% YoY revenue growth, and 0.8x Debt/EBITDA ratio. You can benchmark any stock's competitive durability interactively with our Economic Moat Score™ Checker.
2. Is NVO stock undervalued right now based on P/E and PEG ratio?
Yes — NVO currently screens as undervalued on a growth-adjusted basis with a Peter Lynch PEG ratio of 0.09x (below the 1.2x GARP threshold) and a Forward P/E of 1.7x. At a share price of $39.05, investors can stress-test NVO's fair value using the MoatPicks Economic Moat Score™ Checker and FIRE compounding calculators. Model how compounding NVO fits your long-term retirement target in our FIRE Financial Independence Calculator.
3. Which superinvestors and 13F hedge funds own NVO stock?
Novo Nordisk A/S (NVO) is actively monitored across our 25 tracked 13F superinvestor portfolios and institutional quality screens. Institutional capital focuses on NVO's 82.0% gross margin, $37.7B free cash flow, and 0.8x Debt/EBITDA balance sheet.